Completed Phase 2b Study in Parkinson’s Disease
A Multicenter, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson’s Disease Related Constipation (KARMET).
The study has now completed. The study was conducted at multiple US sites and 95 patients were enrolled over a 6-month period. Escalating doses were administered to 72 patients and titrated to a clinically efficacious or maximum dose, followed by a withdrawal period. Participating sites included Atlanta, Miami, Hershey, Raleigh, Sarasota, Boca Raton, Port Charlotte, Fairfield, Fresno, Las Vegas, Dayton, and others. We would like to thank everyone involved for their support on this important trial.